Skip to content. | Skip to navigation

Personal tools
/ our-people / clinician-scientists / kramer-caroline

  

Dr. Caroline K. Kramer

CLINICIAN SCIENTIST

Dr. Caroline K. Kramer is an Endocrinologist and Clinician Scientist at the Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, and an Assistant Professor in the Division of Endocrinology and Metabolism, Medicine, University of Toronto.

Dr. Kramer’s research program focuses on clinical studies aimed at pinpointing novel factors mediating the interaction between obesity and the development and progression of metabolic disease. Her program studies the impact of brown fat on early metabolic disorders by deep-phenotyping the metabolic changes that take place over time in people with type 2 diabetes, as well as studies the impact of the drug empagliflozin on weight loss and pancreatic function in women with previous gestational diabetes.

She was also co-principal author on a publication describing a new combination therapy for type 2 diabetes, a finding that has the potential to change the clinical management of this disease.

In 2016 Dr. Kramer was awarded the Canadian Diabetes Association Clinician-Scientist Award, for the period 2016-2021. She has also received the New Investigator Award for Diabetes Research from the Banting and Best Diabetes Centre (2015-2017). Her research is funded by CIHR and Heart and Stroke Foundation.

Dr. Kramer obtained her MD degree from the Universidade Federal de Ciencias da Saude do Porto Alegre, Brazil, and her PhD in Endocrinology and Epidemiology from the Universidade Federal Do Rio Grande Do Sul and the University of California San Diego. She undertook post-doctoral fellowship training at the University of Toronto.

She has published more than 80 primary research publications in peer-reviewed journals.

At a Glance

Endocrinologist and Clinician Scientist at the Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, and an Assistant Professor in the Division of Endocrinology and Metabolism, Medicine, University of Toronto.

Focus on novel factors mediating interaction between obesity and development and progression of metabolic disease.

Major Research Activities

Dr. Kramer’s current research projects involve assessing the impact of the drug empagliflozin on pancreatic function in women with previous gestational diabetes, as well as evaluating the effect of brown fat on metabolic health in type 2 diabetes.